Qyuns Therapeutics Co., Ltd. (SEHK: 2509)
Health Care · Biotechnology · CN
HK$17.64
+1.73% today · -35.1% 1Y
Qyuns Therapeutics Co., Ltd. (SEHK: 2509) operates in the Biotechnology industry within the Health Care sector. The company is valued at $502.11M and employs 337 people.
Over the last twelve months the share price has lost 35.1%, trading between 13.21 and 36.50.
Tweenvest scores Qyuns Therapeutics Co., Ltd. across four factors: quality 46/100, value 44/100. Its strongest factor is quality.
2509 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $502.11M
- Revenue (TTM)
- $115.37M
- P/E
- 11.28
- EPS
- 1.41
- Dividend yield
- —
- Beta (5Y)
- 1.49
- 52-week high
- HK$36.50
- 52-week low
- HK$13.21
- Avg volume (3M)
- —
- Shares outstanding
- 223.37M
- Employees
- 337
- Next earnings
- —
About Qyuns Therapeutics Co., Ltd.
Qyuns Therapeutics Co., Ltd., a biotechnology company established in 2015 and headquartered in Taizhou, China, is focused on the discovery and clinical advancement of biologic therapies. Its primary mission is to address autoimmune and allergic diseases within the People's Republic of China. The company boasts a robust pipeline of investigational treatments. Its lead candidate, QX002N, an interleukin (IL)-17A inhibitor, is currently undergoing Phase III clinical trials for the management of ankylosing spondylitis and lupus nephritis. Another key asset, QX005N, a monoclonal antibody engineered to block IL-4Ra, has successfully concluded its Phase II clinical development. This compound targets a wide array of conditions, including atopic dermatitis, prurigo nodularis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria (CSU), asthma, and chronic obstructive pulmonary disease (COPD). Further advanced programs include QX001S, an IL-12/IL-23p40 inhibitor, also in Phase III trials for psoriasis (Ps) and inflammatory bowel diseases such as ulcerative colitis/Crohn's disease (CD). QX004N, an IL-23p19 inhibitor, is progressing through Phase II for Ps and CD. Additionally, early-stage clinical development encompasses QX006N, an IFNAR1-targeting monoclonal antibody in Phase Ib for systemic lupus erythematosus, and QX008N, a humanized IgG1 monoclonal antibody targeting thymic stromal lymphopoietin, also in Phase Ib for moderate-to-severe asthma and COPD. Qyuns is also developing several compounds at an earlier stage, including QX007N, which targets IL-33 for COPD and asthma; QX013N, aimed at c-kit for CSU; and QX010N, an IL-31R inhibitor for pruritus. Beyond its drug development endeavors, the company engages in the research, development, and manufacturing of pharmaceutical products, and provides specialized technical consultation services.
- ISIN
- CNE1000069W9
- Founded
- 2015
- Listed since
- Mar 20, 2024
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.